Instrument Inactif

Communiqués Point Capital Inc Other OTC

Actions

US73052R1041

Recherche biotechnologique et médicale

Communiqués

18/09	Silo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property Portfolio	AQ
09/09	Silo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum	AQ
18/08	Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment	AQ
10/08	Silo Pharma Granted European Patent Covering Novel PTSD Therapy	AQ
06/08	Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform	AQ
21/07	Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program	AQ
14/07	Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform	AQ
10/07	Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules	AQ
07/07	Silo Pharma Subsidiary QwikAgents Set to Advance Enterprise AI Agent Platform through NVIDIA Developer Program	AQ
29/06	Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request	AQ
23/06	Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial	AQ
18/06	Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement	AQ
07/05	Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury	GL
29/04	Silo Pharma : PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD	PU
29/04	Silo Pharma’s PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD	GL
22/04	Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents	GL
20/04	Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics	GL
06/04	Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy	GL
23/02	Silo Pharma Announces Share Buyback Program	GL
18/02	Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio	GL
30/12	Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15	GL
17/11	Silo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSD	GL
29/10/25	Silo Pharma Selects Alphaledger’s T12 Fund for Tokenized Real-World Asset Investments on Solana Blockchain	GL
23/10/25	Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program	GL
09/10/25	Silo Pharma Expands Crypto Treasury with First Strategic Bitcoin Purchase Reinforcing Company's Commitment to Multi-Chain Growth	AQ